Key result
This review discusses the pathophysiology of hypertension in metabolic syndrome and provides a rationale for current therapeutic options based on recent clinical trials.
This review summarizes the pathophysiology and therapeutic options for managing hypertension in patients with metabolic syndrome.
May inform hypertension management in metabolic syndrome; leaves open need for dedicated outcome trials in this population.
Hypertension is a major component of the metabolic syndrome and a major cardiovascular risk factor. Both disorders are rapidly increasing in frequency, with hypertension affecting nearly 60 million Americans and over 1 billion people worldwide, and metabolic syndrome affecting 44% of the US population above the age of 60 years. Sedentary lifestyle, together with obesity and aging of the population, are the major contributing factors for this growing epidemic. Hypertension in metabolic syndrome possesses unique pathophysiological aspects that have considerable implications on therapy of this disease. In this article, we review the pathophysiology and provide a rationale for the current therapeutic options in light of the most recent clinical trials in the field.
No takes yet. Share an insight, caveat, or question.
Ganne et al. (2007) conducted a review in Hypertension in metabolic syndrome. Therapeutic interventions was evaluated. This review discusses the pathophysiology of hypertension in metabolic syndrome and provides a rationale for current therapeutic options based on recent clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: